Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A

被引:44
作者
Castaman, G. [1 ]
Mancuso, M. E. [2 ]
Giacomelli, S. H. [1 ]
Tosetto, A. [1 ]
Santagostino, E. [2 ]
Mannucci, P. M. [2 ]
Rodeghiero, F. [1 ]
机构
[1] San Bortolo Hosp, Dept Cell Therapy & Hematol, Hemophilia & Thrombosis Ctr, I-36100 Vicenza, Italy
[2] Univ Milan, Dept Med & Med Specialties, IRCCS Maggiore Hosp,Mangiagalli & Regina Elena Fd, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
关键词
desmopressin; factor VIII; FVIII gene mutation; mild hemophilia A; von Willebrand factor; VON-WILLEBRAND-FACTOR; FACTOR-VIII GENE; VONWILLEBRANDS DISEASE; CRYSTAL-STRUCTURE; DDAVP; MUTATIONS; PHARMACOKINETICS; SPECTRUM; VWD;
D O I
10.1111/j.1538-7836.2009.03595.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The relationship of the biologic response to desmopressin with the F8 mutation and physiological characteristics has been poorly investigated in patients with mild hemophilia A. Objectives: We prospectively assessed the molecular and phenotypic determinants of the biologic response to desmopressin in a cohort of 50 patients with mild hemophilia A. Methods: Up to 24 h after desmopressin, blood samples were serially obtained and factor (F)VIII and von Willebrand factor (VWF) measured. The promoter region, all exons and exon-intron boundaries of the F8 gene were screened using denaturing high-performance liquid chromatography (DHPLC). Direct sequencing was done when DHPLC screening was normal. Genomic DNA was also sequenced for exons 18-21, 24 and 27 of VWF. Results: Mean basal FVIII:C was 19 +/- 9 IU dL-1 (range 6-37) and the median postdesmopressin peak increase was 2.5-fold (range 1.1-7.1). Eleven patients with a cross-reacting material positive (CRM+) phenotype had similar basal levels and relative increases of FVIII:C to the remaining patients with low FVIII:Ag. Using multivariate regression, FVIII:C half-life was positively related to basal and peak VWF:Ag levels (P = 0.008) and patient age (P = 0.004). Eleven patients had evidence of reduced FVIII survival. While 27 different gene mutations were identified in 41 patients, nine patients had no detectable mutation. These patients had significantly smaller peaks and smaller relative increase of postdesmopressin FVIII:C (median FVIII:C 26 IU dL-1 vs. 54 IU dL-1; P < 0.001; fold 1.8 +/- 0.6 vs. 2.9 +/- 0.8; P = 0.002). Conclusions: In this cohort of patients with mild hemophilia A, a poor biologic response to desmopressin was frequently associated with the absence of detectable F8 mutations.
引用
收藏
页码:1824 / 1831
页数:8
相关论文
共 31 条
[1]  
Acquila M, 2004, HAEMATOLOGICA, V89, P758
[2]  
[Anonymous], HAMSTERS DATABASE
[3]   Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A [J].
Bogdanova, Nadja ;
Markoff, Arseni ;
Eisert, Roswith ;
Wermes, Cornelia ;
Pollmann, Hartmut ;
Todorova, Albena ;
Chlystun, Marcin ;
Nowak-Goettl, Ulrike ;
Horst, Juergen .
HUMAN MUTATION, 2007, 28 (01) :54-60
[4]   The evaluation of factor VIII binding activity of von willebrand factor by means of an ELISA method - Significance and practical implications [J].
Casonato, A ;
Pontara, E ;
Zerbinati, P ;
Zucchetto, A ;
Girolami, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 109 (03) :347-352
[5]  
Castaman G, 2008, HAEMOPHILIA, V14, P15, DOI 10.1111/j.1365-2516.2007.01606.x
[6]   Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene [J].
Castaman, G. ;
Giacomelli, S. H. ;
Ghiotto, R. ;
Boseggia, C. ;
Pojani, K. ;
Bulo, A. ;
Madeo, D. ;
Rodeghiero, F. .
HAEMOPHILIA, 2007, 13 (03) :311-316
[7]   Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD [J].
Castaman, Giancarlo ;
Lethagen, Stefan ;
Federici, Augusto B. ;
Tosetto, Alberto ;
Goodeve, Anne ;
Budde, Ulrich ;
Batlle, Javier ;
Meyer, Dominique ;
Mazurier, Claudine ;
Fressinaud, Edith ;
Goudemand, Jenny ;
Eikenboom, Jeroen ;
Schneppenheim, Reinhard ;
Ingerslev, Jorgen ;
Vorlova, Zdena ;
Habart, David ;
Holmberg, Lars ;
Pasi, John ;
Hill, Frank ;
Peake, Ian ;
Rodeghiero, Francesco .
BLOOD, 2008, 111 (07) :3531-3539
[8]   Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia A and inhibitors [J].
d'Oiron, R ;
Volot, F ;
Reynaud, J ;
Peerlinck, K ;
Goudemand, J ;
Guérois, C ;
Rothschild, C ;
Chambost, H ;
Borel-Derlon, A ;
Roussel-Robert, V ;
Marqués-Verdier, A ;
Lienhart, A ;
Berthier, AM ;
Moreau, P ;
Lambert, T .
SEMINARS IN HEMATOLOGY, 2006, 43 (01) :S3-S9
[9]   RESPONSE OF PATIENTS WITH MILD AND MODERATE HEMOPHILIA-A AND VONWILLEBRANDS DISEASE TO TREATMENT WITH DESMOPRESSIN [J].
DELAFUENTE, B ;
KASPER, CK ;
RICKLES, FR ;
HOYER, LW .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (01) :6-14
[10]   Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene [J].
El-Maarri, O ;
Herbiniaux, U ;
Graw, J ;
Schröder, J ;
Terzic, A ;
Watzka, M ;
Brackmann, HH ;
Schramm, W ;
Hanfland, P ;
Schwaab, R ;
Müller, CR ;
Oldenburg, J .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) :332-339